Navigation Links
New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
Date:4/28/2008

Software enables clinical-trial researchers, analysts and managers to visualize and collaborate across the room or around the world, in real-time

SCOTTSDALE, Ariz., April 28 /PRNewswire/ -- General Dynamics Viz, a part of General Dynamics C4 Systems, introduces CoMotion(R) Trials, a collaborative, decision-support software tool that enables hundreds of researchers, analysts and managers to see, analyze, share and comment on data and information produced throughout the clinical trials process. The software, which runs on a commercial off-the-shelf computer, integrates data from many separate systems, portraying it in easily configurable charts and visualizations.

Required by the U.S. government, clinical trials comprise rigorous research, testing and analysis of the safety and effectiveness of new pharmaceuticals and medical equipment. A clinical trial can last several years and involve measurement and analysis of information from thousands of patients in hospitals, clinics or other medical facilities located worldwide. As more trials adopt computer-based systems to capture electronic data, the volume and complexity of information increases. As a result, software-based tools are needed to streamline the organization, interpretation and decision-making responsibilities that clinical trials teams must complete.

"With this software, clinical trials stakeholders don't have to stitch emails, wikis and sticky-notes together for the big-picture view of what's happening during a clinical trial," said Mike Capsambelis, product management director for General Dynamics Viz. "CoMotion Trials streamlines the flow of information during every phase of the clinical trials process, and that means significant cost and time savings for everyone involved."

CoMotion Trials is built on General Dynamics' CoMotion(R) software technology, currently used in the life sciences industry and by the U.S. government and military. For the military, CoMotion is part
'/>"/>

SOURCE General Dynamics C4 Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
3. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
4. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
8. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
11. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 2HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 3AMERIGROUP Corporation Names Two New Executives 58138 1AMERIGROUP Corporation Names Two New Executives 58138 2AMERIGROUP Corporation Names Two New Executives 58138 3Bubble Trouble Team Hits the Lab for Good Hygiene 58133 1Bubble Trouble Team Hits the Lab for Good Hygiene 58133 2Bubble Trouble Team Hits the Lab for Good Hygiene 58133 3Bubble Trouble Team Hits the Lab for Good Hygiene 58133 4Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 1Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 2Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31 2009 14227 3
Other Medicine Technology:New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 2New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 3New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 4New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 2Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 3Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 4Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 6Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 7
Other Medicine News:Health News:Baxter Reports Strong Third Quarter Sales and Earnings 2Health News:Baxter Reports Strong Third Quarter Sales and Earnings 3Health News:Baxter Reports Strong Third Quarter Sales and Earnings 4Health News:Baxter Reports Strong Third Quarter Sales and Earnings 5Health News:Baxter Reports Strong Third Quarter Sales and Earnings 6Health News:Baxter Reports Strong Third Quarter Sales and Earnings 7Health News:Baxter Reports Strong Third Quarter Sales and Earnings 8Health News:Baxter Reports Strong Third Quarter Sales and Earnings 9Health News:Baxter Reports Strong Third Quarter Sales and Earnings 10Health News:Baxter Reports Strong Third Quarter Sales and Earnings 11Health News:Baxter Reports Strong Third Quarter Sales and Earnings 12Health News:Baxter Reports Strong Third Quarter Sales and Earnings 13Health News:Baxter Reports Strong Third Quarter Sales and Earnings 14Health News:Baxter Reports Strong Third Quarter Sales and Earnings 15Health News:Baxter Reports Strong Third Quarter Sales and Earnings 16Health News:Baxter Reports Strong Third Quarter Sales and Earnings 17Health News:Baxter Reports Strong Third Quarter Sales and Earnings 18Health News:Baxter Reports Strong Third Quarter Sales and Earnings 19Health News:Baxter Reports Strong Third Quarter Sales and Earnings 20Health News:Baxter Reports Strong Third Quarter Sales and Earnings 21Health News:Baxter Reports Strong Third Quarter Sales and Earnings 22Health News:Baxter Reports Strong Third Quarter Sales and Earnings 23Health News:Baxter Reports Strong Third Quarter Sales and Earnings 24Health News:Baxter Reports Strong Third Quarter Sales and Earnings 25Health News:Baxter Reports Strong Third Quarter Sales and Earnings 26Health News:Baxter Reports Strong Third Quarter Sales and Earnings 27Health News:Baxter Reports Strong Third Quarter Sales and Earnings 28Health News:XTend Medical (XDMC) Adds New Bluetooth(R) Telemedicine Products From A&D Medical 2Health News:Holiday Gifts That Help Fight Alzheimer's Disease 2Health News:QLT announces Visudyne(R) sales for third quarter and provides Visudyne sales guidance for 2007 2Health News:QLT announces Visudyne(R) sales for third quarter and provides Visudyne sales guidance for 2007 3Health News:Practices in Health & Disability Insurance - The Lives & Wealth They Cost America 2